Tempus AI, Inc. Class A Common Stock (NYSE: TEM) — Perfil da empresa, notícias e dados financeiros
Tempus AI, Inc.
Tempus AI, Inc. Class A Common Stock
Tempus AI, Inc. Class A Common Stock is a technology company focused on advancing precision medicine through the application of artificial intelligence in healthcare. The company operates a proprietary technology platform that collects, structures, and analyzes clinical and molecular data to assist healthcare providers in making personalized treatment decisions. Its solutions serve medical practitioners, researchers, and biotechnology and pharmaceutical partners primarily across oncology, neurology, psychiatry, and cardiology. By integrating multimodal datasets including genomic sequencing results, digital pathology, and clinical records, the company enables data-driven insights to accelerate clinical trial recruitment, drug discovery, and individualized patient care.
Resumo
Operações
Produtos e/ou serviços de Tempus AI, Inc. Class A Common Stock
- Genomic Testing Services: Comprehensive next-generation sequencing assays covering DNA and RNA for oncology, cardiology, and neuropsychiatry, providing clinicians with actionable genomic profiles to guide therapeutic decision-making and targeted disease management.
- Data and Analytics Licensing: Structuring and licensing de-identified multimodal healthcare datasets, combining clinical records with molecular data to support pharmaceutical and biotechnology partners in therapeutic research, biomarker discovery, and population health analysis.
- Clinical Trial Matching and Operations: AI-enabled patient recruitment and clinical trial matching services that identify eligible candidates across network clinical sites using real-world clinical and genomic data to accelerate biopharmaceutical trial enrollment and pipeline execution.
- Companion Diagnostics and Laboratory Services: Co-development and commercialization of diagnostic assays in partnership with life sciences entities, delivering custom molecular assay design, CLIA-certified central laboratory testing, and regulatory support pathways to validate biopharmaceutical targeted therapies.
- Digital Pathology and Radiology Tools: Advanced image analysis algorithms and digital pathology platforms that integrate whole-slide imaging and radiological data with clinical records to assist pathologists and radiologists in diagnostic workflows and diagnostic risk stratification.
- Clinical Decision Support Applications: Interactive software tools and artificial intelligence assistants embedded in clinical workflows, enabling healthcare providers to query patient records, review clinical guidelines, and access real-time diagnostic insights at the point of care.
equipe executiva do Tempus AI, Inc. Class A Common Stock
- Eric P. LefkofskyCo-Founder, CEO, President & Chairman
- James RogersChief Financial Officer
- Erik PhelpsExecutive VP and Chief Administrative & Legal Officer
- Andrew PolovinChief Legal Officer
- Ryan FukushimaChief Executive Officer of Data & Apps
- Ryan M. BartolucciChief Accounting Officer
- Shane ColleyChief Technology Officer
- Kate A. SasserChief Scientific Officer
- Elizabeth KrutoholowVice President of Investor Relations & Competitive Intelligence
- Christina AntoniouSenior VP & Head of Corporate Development
Últimas notícias sobre a Tempus AI, Inc. Class A Common Stock
Principais indicadores financeiros
Resultados divulgados pela Tempus AI, Inc. Class A Common Stock, em USD.
- Cap. de mercado
- 13,1 bi
- Receita (TTM)
- 1,4 bi
- P/L
- —
- LPA (diluído, TTM)
- -1.6
- Dividend yield
- —
- Margem de lucro
- -17.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,3 bi | -252,9 mi | -245 mi | |
| 693,4 mi | -691,1 mi | -705,8 mi | |
| 531,8 mi | -196,1 mi | -214,1 mi | |
| 320,7 mi | -265,4 mi | -289,8 mi |